In vivo and in vitro estrogenic and progestagenic actions of Tibolone
Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones w...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2005-01-01
|
| Series: | Biological Research |
| Subjects: | |
| Online Access: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014 |
| _version_ | 1819266320715218944 |
|---|---|
| author | ANIL SADARANGANI ANA MARÍA SALGADO SUMIE KATO MAURICIO PINTO ANDRÉS CARVAJAL CAROLINA MONSO GARETH I OWEN PILAR VIGIL |
| author_facet | ANIL SADARANGANI ANA MARÍA SALGADO SUMIE KATO MAURICIO PINTO ANDRÉS CARVAJAL CAROLINA MONSO GARETH I OWEN PILAR VIGIL |
| author_sort | ANIL SADARANGANI |
| collection | DOAJ |
| description | Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones would be clinically advantageous. However, data from the Million Women Study suggests that Tibolone increases the risk of both breast and endometrial cancer. Herein, we assessed the estrogenic and progestagenic actions of Tibolone using transvaginal sonography studies and an in vitro model of breast (ZR-75, MCF7) and endometrial cancer (Ishikawa). The known cancer associated proteins (ER, EGFR, STAT5, tissue factor and Bcl-xL) were selected for study. Transvaginal sonography demonstrated that postmenopausal women treated with Tibolone displayed a thinner endometrium than in the late proliferative phase, but had a phenotype characteristic of the secretory phase, thus demonstrating the estrogenic and progestagenic actions of this SERM. In vitro, Tibolone acted as an estrogen in downregulating ER and upregulating Bcl-xL, yet as progesterone, increasing STAT5 and tissue factor in breast cancer cells. The increase in tissue factor by Tibolone correlated with its coagulative potential. Interestingly, EGFR was up-regulated by progesterone in the breast and by estrogen in endometrial cells, while Tibolone increased protein levels in both cell types. In conclusion, this study further demonstrates the estrogenic and progestagenic nature of Tibolone. The pattern of regulation of known oncogenes in cells of breast and endometrial origin dictates caution and vigilance in the prescription of Tibolone and subsequent patient monitoring |
| first_indexed | 2024-12-23T20:59:24Z |
| format | Article |
| id | doaj.art-f68dde2764764f77b3f8b517ebea6a0f |
| institution | Directory Open Access Journal |
| issn | 0716-9760 0717-6287 |
| language | English |
| last_indexed | 2024-12-23T20:59:24Z |
| publishDate | 2005-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Biological Research |
| spelling | doaj.art-f68dde2764764f77b3f8b517ebea6a0f2022-12-21T17:31:25ZengBMCBiological Research0716-97600717-62872005-01-01382-3245258In vivo and in vitro estrogenic and progestagenic actions of TiboloneANIL SADARANGANIANA MARÍA SALGADOSUMIE KATOMAURICIO PINTOANDRÉS CARVAJALCAROLINA MONSOGARETH I OWENPILAR VIGILEstrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones would be clinically advantageous. However, data from the Million Women Study suggests that Tibolone increases the risk of both breast and endometrial cancer. Herein, we assessed the estrogenic and progestagenic actions of Tibolone using transvaginal sonography studies and an in vitro model of breast (ZR-75, MCF7) and endometrial cancer (Ishikawa). The known cancer associated proteins (ER, EGFR, STAT5, tissue factor and Bcl-xL) were selected for study. Transvaginal sonography demonstrated that postmenopausal women treated with Tibolone displayed a thinner endometrium than in the late proliferative phase, but had a phenotype characteristic of the secretory phase, thus demonstrating the estrogenic and progestagenic actions of this SERM. In vitro, Tibolone acted as an estrogen in downregulating ER and upregulating Bcl-xL, yet as progesterone, increasing STAT5 and tissue factor in breast cancer cells. The increase in tissue factor by Tibolone correlated with its coagulative potential. Interestingly, EGFR was up-regulated by progesterone in the breast and by estrogen in endometrial cells, while Tibolone increased protein levels in both cell types. In conclusion, this study further demonstrates the estrogenic and progestagenic nature of Tibolone. The pattern of regulation of known oncogenes in cells of breast and endometrial origin dictates caution and vigilance in the prescription of Tibolone and subsequent patient monitoringhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014breast/endometrium cancerestrogenicHRTprogestagenic & tibolone |
| spellingShingle | ANIL SADARANGANI ANA MARÍA SALGADO SUMIE KATO MAURICIO PINTO ANDRÉS CARVAJAL CAROLINA MONSO GARETH I OWEN PILAR VIGIL In vivo and in vitro estrogenic and progestagenic actions of Tibolone Biological Research breast/endometrium cancer estrogenic HRT progestagenic & tibolone |
| title | In vivo and in vitro estrogenic and progestagenic actions of Tibolone |
| title_full | In vivo and in vitro estrogenic and progestagenic actions of Tibolone |
| title_fullStr | In vivo and in vitro estrogenic and progestagenic actions of Tibolone |
| title_full_unstemmed | In vivo and in vitro estrogenic and progestagenic actions of Tibolone |
| title_short | In vivo and in vitro estrogenic and progestagenic actions of Tibolone |
| title_sort | in vivo and in vitro estrogenic and progestagenic actions of tibolone |
| topic | breast/endometrium cancer estrogenic HRT progestagenic & tibolone |
| url | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014 |
| work_keys_str_mv | AT anilsadarangani invivoandinvitroestrogenicandprogestagenicactionsoftibolone AT anamariasalgado invivoandinvitroestrogenicandprogestagenicactionsoftibolone AT sumiekato invivoandinvitroestrogenicandprogestagenicactionsoftibolone AT mauriciopinto invivoandinvitroestrogenicandprogestagenicactionsoftibolone AT andrescarvajal invivoandinvitroestrogenicandprogestagenicactionsoftibolone AT carolinamonso invivoandinvitroestrogenicandprogestagenicactionsoftibolone AT garethiowen invivoandinvitroestrogenicandprogestagenicactionsoftibolone AT pilarvigil invivoandinvitroestrogenicandprogestagenicactionsoftibolone |